SCHEMBL2156599

SCHEMBL2156599

O=C(C(=O)c1ccc(O)c([N+](=O)[O-])c1)c1ccc(O)c([N+](=O)[O-])c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.60
GPR35 Q9HC97 2/20 0.60
TSHR P16473 2/20 0.60
ALDH1A1 P00352 1/20 0.60
TP53 P04637 1/20 0.60
HPGD P15428 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
L3MBTL1 Q9Y468 2/20 0.58
ALOX15 P16050 1/20 0.58
HSD17B10 Q99714 1/20 0.58
CES1 P23141 3/20 0.56
CES2 O00748 2/20 0.56
ALDH5A1 P51649 1/20 0.55
ABAT P80404 1/20 0.55
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
CASP6 P55212 1/20 0.53
KDM4E B2RXH2 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9660912 0.91 GPR35 (0.55) MAPK1GPR35TSHRALDH1A1TP53
SCHEMBL7103159 0.88 VCAM1 (0.65) MAPK1GPR35TSHRALDH1A1TP53
SCHEMBL106249 0.86 CASP6 (0.72) MAPK1GPR35TSHRALDH1A1TP53
SCHEMBL2636747 0.86 CASP6 (0.72) MAPK1GPR35TSHRALDH1A1TP53
SCHEMBL764067 0.85 PARP1 (0.67) MAPK1GPR35TSHRALDH1A1TP53
SCHEMBL532487 0.85 MAPK1 (0.56) MAPK1GPR35TSHRALDH1A1TP53
SCHEMBL1898142 0.85 CASP6 (0.70) MAPK1GPR35TSHRALDH1A1TP53
SCHEMBL30527129 0.85 MAPK1 (0.56) MAPK1GPR35TSHRALDH1A1TP53
SCHEMBL9469173 0.85 CA1 (0.58) MAPK1GPR35TSHRALDH1A1TP53
SCHEMBL9469176 0.85 CASP6 (0.70) MAPK1GPR35TSHRALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973034-B2 Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2011-07-05 US claimed
US-7973034-B2 Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2011-07-05 US disclosed
US-7973034-B2 Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2011-07-05 US disclosed
US-7973034-B2 Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2011-07-05 US disclosed
US-20080146548-A1 AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2008-06-19 US disclosed
US-20080146548-A1 AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2008-06-19 US disclosed
US-20080146548-A1 AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146548-A1 AMIDE, ARYL SULFONAMIDE, ARYL UREA, AND a,b-DIKETONE DERIVED CARBOXYLESTERASE INHIBITORS, AND THEIR METHODS OF USE CES1, BCHE, CES2 MAPK1 3924/4885GPR35 3421/4885TSHR 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.